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INTRODUCTION
Cancer antigen 125 (CA125) is widely used as a biomarker for 
evaluating disease status and monitoring the efficacy of chemo-
therapy in patients with epithelial ovarian cancer (EOC). Parallel 
changes in CA125 levels and cancer growth have been reported 
in EOC. As a result, CA125 levels and changes in CA125 levels 
during treatment have been extensively investigated.
Previous studies demonstrate the prognostic or predictive val-
ues of single values (e.g., nadirs, normalizations, or thresholds)1-6 
or kinetic parameters on two time points, such as percentage 
decrease,7,8 half-life,9-12 or area-under-the curve (AUC).13
The Gynecologic Cancer Intergroup (GCIG) defined CA125 
response as a 50% reduction in CA125 levels compared to that 
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of a pre-treatment sample; the response must be confirmed 
and maintained for at least 28 days.14 However, in a recent clin-
ical trial, an early decline in CA125 levels was not a surrogate 
marker for the efficacy of pegylated liposomal doxorubicin with 
carboplatin.15 Lee, et al.8 analysed CA125 reductions in patients 
enrolled in this trial and reported paradoxical outcomes regard-
ing the prognostic value of the GCIG-defined CA125 response.
Thus, previous outcomes about most useful value of CA125 
remain controversial. The limited researches have investigat-
ed the most reliable and significant method for anticipating 
survival outcomes among the numerous prediction methods 
that use CA125. Therefore, the optimal method for predicting 
patient prognosis remains unknown.
The objective of this study was to identify the most powerful 
CA125-related significant prognostic factors for patients with 
EOC. We compared known CA125-related prognostic factors 
and provided cut-off values that differentiated patients into 
subgroups of favorable and poor survival outcomes.
MATERIALS AND METHODS
Patient populations
Patients who underwent staging laparotomy at the Severance 
and Gangnam Severance Hospital between March 2004 and 
March 2013 were included in this study. Inclusion criteria were 
as follows: 1) serous histological type ovarian cancer; 2) ad-
vanced International Federation of Gynecology and Obstetrics 
(FIGO) stage IIC–IV; 3) more than six cycles of taxane+platin-
um-based first-line chemotherapy after primary debulking sur-
gery; 4) serially measured CA125 values; and 5) clinical and 
radiological assessment during follow-up or recurrences. Fi-
nally, the study included 223 patients. Elevated CA125 levels 
are found in >90% of patients with advanced-stage disease, 
but in only 50% of patients with stage I disease.16 Normal serum 
CA125 levels are occasionally found in mucinous or endome-
trioid ovarian cancers, whereas elevated CA125 levels are 
most frequently observed in serous cancer.17 In this study, ad-
vanced stage patients with serous EOC were included to en-
sure a homogeneous study population. Patients with border-
line malignancies treated with neoadjuvant chemotherapy 
and patients who did not receive staging laparotomy at Sever-
ance or Gangnam Severance Hospitals were excluded.
All patients received standard staging and debulking sur-
geries from gynecologic oncological specialists based on FIGO 
recommendations.18 The first cycle of a taxane plus platinum-
based chemotherapy regimen was started an average of 17±10 
days after surgery. Six to ten courses of postoperative adjuvant 
chemotherapy (POAC) were administered at approximately 
three-week intervals.
This study was approved by the Institutional Review Boards 
of Severance Hospital and Gangnam Severance Hospital. Some 
sera for CA125 assay were provided by Korea Gynecologic Can-
cer Bank through Bio & Medical Technology Development 
Program of the Ministry of Education, Science and Technolo-
gy, Korea.
Clinicopathological characteristics
The following clinicopathological data were obtained from 
medical records: age, FIGO stage, histological type and grade, 
pathological result, type of primary treatment (type of surgery 
and adjuvant chemotherapy), surgical findings (mass size, as-
cites volume, residual mass size), CA125 level, surgery date, 
chemotherapy cycle and date, recurrence date, date of last visit, 
and date of death.
Histologic slides were reviewed by gynecologic pathologists, 
and histologic types were identified according to World Health 
Organization (WHO) criteria.19 The histologic grades of well-
differentiated, moderately differentiated, and poorly differenti-
ated tumours were classified as grades 1, 2, and 3, respectively.
Operative mass size was classified as either <5 cm or ≥5 cm, 
and ascites volume was classified as either <500 or ≥500 mL. A 
residual mass <1 cm after primary surgery was defined as op-
timal debulking surgery, whereas a residual mass of ≥1 cm 
was defined as suboptimal debulking surgery.
The treatment start date was defined as the date on which 
surgical staging was performed. The date of the last visit was 
defined as the date of the last recorded visit for the patient to ei-
ther the gynaecology department or any other department. The 
recurrence date was defined as the date on which newly devel-
oped lesions were confirmed by computed tomography (CT), 
positron emission tomography (PET)-CT, or magnetic reso-
nance imaging (MRI) based on elevated CA125 levels or clinical 
exams.
Overall survival (OS) and progression free survival (PFS) rates 
were calculated from the date of the first treatment to the date 
of death (last visit for surviving patients) and from the date of 
the first treatment to the date of recurrence (last visit in the ab-
sence of recurrence), respectively.
CA125 assay
Pre-operative serum CA125 levels were measured within two 
weeks of the first surgery and approximately three weeks after 
each chemotherapy cycle, which was 1–3 days before the begin-
ning of the subsequent chemotherapy cycle. CA125 immunoas-
says were performed using a Beckman DXI (Beckman Coulter, 
Inc., Brea, CA, USA) at Severance Hospital and a Modular Analyt-
ics E170 (Roche Diagnostics, Indianapolis, IN, USA) at Gangnam 
Severance Hospital according to manufacturer recommenda-
tions. All assays were performed in duplicate, and the reference 
range for normal CA125 levels was defined as ≤35 U/mL.
CA125 kinetics
The CA125 nadir was defined as the absolute lowest CA125 val-
ue after the start of chemotherapy. The time to nadir was de-
fined as the duration from the date of the first treatment to the 
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date of the minimum value.
CA125 half-life (T1/2) was calculated based on mono-com-
partment models and exponential regression in accordance 
with earlier studies.20-22 For the regression line calculation, at 
least three serial and aligned ln CA125 concentrations were re-
quired from the first six blood samples.
Half-life=ln 2/s, 
in which was the slope of the regression curve that reflected 
the effects of surgery and chemotherapy.
S=ln C1-ln C2/t2-t1=ln C1/C2/t2-t1.
Therefore, half-life=ln 2×(t2-t1)/ln C1/C2.
C1 was the CA125 value before the first treatment, and C2 
was the value at which CA125 decreased to <35 U/mL for the 
first time. If the CA125 level never decreased to <35 U/mL with-
in three months of starting chemotherapy, the lowest value 
during that period was selected. The times (in days) for C1 
and C2 were given as t1 and t2, respectively.
Statistical analysis
Univariate and multivariate Cox model analyses were used to 
investigate the effects of each clinicopathological prognostic 
factor on OS and PFS. For the statistical analysis of CA125-re-
lated prognostic factors, univariate Cox regression analysis was 
first performed with each variable and statistically significant 
variables were selected. Multivariate Cox regression analysis 
using stepwise selection was performed, and the most signifi-
cant indicator of OS and PFS was then determined. Two meth-
ods were utilized for determining optimal cut-off values of 
each variable. First, the cut-off values that showed statistically 
significant outcomes regarding OS and PFS in earlier studies 
were used for the variables of pre-operative CA125, CA125 lev-
els after the first and second chemotherapy cycles, time to nor-
malization, and relative percentage change in CA125.4,10,20,23 
Second, for the variables of nadir, time to nadir, CA125 half-
life, and CA125 levels after the sixth chemotherapy cycle, the 
median was used to determine the cut-off value, because it was 
useful for dividing the group into two parts. Receiver operat-
ing characteristic analysis revealed a low AUC without signifi-
cance when death or recurrence was selected as an event. Con-
sequently, the cut-off values were as follows: pre-operative 
CA125 levels, 500 U/mL; CA125 levels after the first and sec-
ond chemotherapy cycles, 35 U/mL; CA125 levels after the 
sixth chemotherapy cycle, 9 U/mL; CA125 levels at nadir, 8 U/
mL; time to nadir, 160 days; time to normalization, third cycle; 
CA125 half-life, three days; and CA125 relative percentage 
change, 71%.
Statistical analyses were performed with the software pack-
age IBM SPSS Version 20.0 (SPSS Inc., Chicago, IL, USA). For 
all tests, all p values were two-sided, and p<0.05 was consid-
ered statistically significant.
RESULTS
Patient demographics
Two hundred and twenty-three patients who met the inclu-
Table 1. Univariate and Multivariate Cox Model Analyses of Clinicopathological Characteristics for Overall Survival (n=223)
Variables No. (%)
Univariate Multivariate
p value HR (95% CI) p value HR (95% CI)
Age
≤50 yrs 89 (39.9) 1 1
>50 yrs 134 (60.1) 0.335 1.28 (0.78–2.10) 0.272 1.40 (0.77–2.52)
FIGO stage
IIC or III 182 (81.6) 1 1
IV 41 (18.4) <0.001 2.81 (1.67–4.75) 0.049 1.88 (1.0–3.51)
Grade
1 15 (6.7) 1 1
2 80 (35.9) 0.086 5.79 (0.78–42.85) 0.223 3.52 (0.47–26.73)
3 107 (48.0) 0.086 5.74 (0.78–42.08) 0.235 3.38 (0.45–25.34)
Residual tumour 
<1 cm 166 (74.4) 1 1
≥1 cm 45 (20.2) 0.026 1.90 (1.08–3.34) 0.367 1.36 (0.70–2.65)
Ascites
<500 mL 106 (47.5) 1 1
≥500 mL 115 (51.6) <0.001 3.05 (1.79–5.21) 0.015 2.19 (1.17–4.10)
Chemotherapy cycles
6 178 (79.8) 1 1
>6 45 (20.2) 0.049 1.70 (1.00–2.87) 0.033 1.98 (1.06–3.71)
FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval; HR, hazard ratio.
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sion criteria were included in this study. Patient characteristics 
and the results of survival analysis regarding the clinicopatho-
logical variables are shown in Table 1. The median patient age 
was 53 years (range, 25–81 years). Most (75.8%) patients had 
stage IIIC cancer; 80 patients (35.9%) were grade 2, and 107 pa-
tients (48.0%) were grade 3 at the time of diagnosis. One hun-
dred and sixty-six patients (74.4%) received optimal debulking 
surgery, and 45 patients (20.2%) had residual tumours >1 cm. 
One hundred and seventy-eight patients (79.8%) received six 
cycles of taxane+platinum-based POAC, and 45 patients (20.2%) 
received seven to ten cycles. Univariate analysis showed that 
stage, largest diameter of residual tumour, ascites volume, and 
number of POAC cycles were prognostic factors for OS. Multi-
variate analysis showed that stage, ascites volume, and num-
ber of POAC cycles were prognostic factors for OS.
Distribution of CA125-related parameters
In the present study, the median pre-operative CA125 value in 
patients with stage IIC–IV serous ovarian cancer was 787.8 U/
mL (range, 13.0–12001.0 U/mL), and CA125 median values af-
ter the first, second, and sixth chemotherapy cycles were 43.4 
(range, 6.6–2677.2), 17.1 (range, 5.1–3954.5), and 8.8 (range, 
2.2–9845.5) U/mL, respectively. The median CA125 nadir lev-
el was 7.9 U/mL (range, 2.0–2677.2 U/mL), median time to 
nadir was 165.0 days (range, 37.0–929.0 days), and median 
CA125 half-life was 3.1 days (range, 1.5–188.4 days). The me-
dian relative percentage change in CA125 compared to that at 
baseline after the first and second chemotherapy cycles were 
91.7% and 96.8%, respectively.
Prognostic impact of CA125-related variables
Survival analyses were performed for the following 10 criteria: 
1) pre-operative CA125 level; CA125 levels after the 2) first, 3) 
second, and 4) sixth chemotherapy cycles; 5) nadir; 6) time to 
nadir; 7) time to normalization; 8) half-life; and the relative 
percentage change from baseline to the 9) first and 10) second 
cycles of chemotherapy.
Each variable was divided into two groups based on the pre-
viously mentioned method.
Univariate Cox regression showed that seven variables [pre-
operative CA125 level, CA125 levels after the first, second, and 
sixth chemotherapy cycles, nadir, time to normalization, and 
relative percentage change (baseline to after first chemotherapy 
cycle)] were significant prognostic factors for OS; six variables 
[pre-operative CA125 level, CA125 levels after the first and sec-
ond chemotherapy cycles, time to normalization, half-life, rela-
tive percentage change (baseline to after first chemotherapy 
cycle)] were significant prognostic factors for PFS (Table 2).
To determine the most significant prognostic factors for OS 
and PFS, multivariate Cox regression, using stepwise regres-
sion techniques was performed with the variables that showed 
significant outcomes in univariate analysis. As a result, the 
CA125 level measured after the first chemotherapy cycle, time 
to CA125 normalization, and relative percentage change of 
Table 2. Univariate Analysis of CA125-related Prognostic Factors for Overall Survival and Progression Free Survival
Prognostic factor Categories
OS PFS
p value HR (95% CI) p value HR (95% CI)
Pre-operative CA125
≤500 u/mL 1 1 
>500 u/mL 0.011 1.94 (1.17–3.24) 0.002 1.68 (1.22–2.31)
After 1st CTx
≤35 u/mL 1 1 
>35 u/mL <0.001 4.46 (2.49–7.99) <0.001 2.30 (1.66–3.19)
After 2nd CTx
≤35 u/mL 1 1 
>35 u/mL <0.001 2.85 (1.74–4.66) <0.001 2.65 (1.88–3.73)
After 6th CTx
≤9 u/mL 1 1 
>9 u/mL 0.008 1.93 (1.19–3.15) 0.47 1.38 (1.00–1.88)
Nadir
≤8 u/mL 1 1 
>8 u/mL 0.028 1.69 (1.06–2.68) 0.53 1.35 (1.00–1.84)
Time to nadir
≤160 days 1 1 
>160 days 0.177 0.73 (0.46–1.16) 0.068 0.75 (0.55–1.02)
Time to normalization
≤3rd cycle 1 1 
>3rd cycle <0.001 3.57 (2.00–6.38) <0.001 3.84 (2.50–5.88)
CA125 half-life
≤3 days 1 1 
>3 days 0.129 0.70 (0.44–1.11) 0.021 0.70 (0.51–0.95)
Relative change (base–after 1st CTx)
>71% 1 1 
≤71% 0.001 0.42 (0.25–0.71) 0.031 0.66 (0.45–0.96)
Relative change (base–after 2nd CTx)
>71% 1 1 
≤71% 0.700 0.86 (0.39–1.87) 0.126 1.61 (0.88–2.98)
OS, overall survival; PFS, progression free survival; CI, confidence interval; HR, hazard ratio; CTx, chemotherapy; CA125, cancer antigen 125.
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CA125, compared to that at baseline after the first chemother-
apy cycle, were sequentially selected for OS; time to CA125 
normalization followed by CA125 level after the first chemo-
therapy cycle was selected for PFS (Table 3).
The CA125 level measured after the first chemotherapy cy-
cle was selected as the most significant factor for OS and the 
second most significant prognostic factor for PFS, and was di-
vided into two groups by the cut-off value of 35 U/mL. Kaplan-
Meier analysis was then performed. The five-year OS rates 
were 87.4% and 56.9% for patients with CA125 levels ≤35 U/
mL and >35 U/mL, respectively, after the first chemotherapy 
cycle (p<0.001). The prognosis for two-year PFS manifested 
differences of 69.7% and 36.7%, respectively (p<0.001) (Fig. 1). 
Kaplan-Meier analysis of the time to normalization, which was 
selected as the second highest factor for OS and the most sig-
nificant prognostic factor for PFS, determined that patients who 
did not show normal CA125 values within three chemothera-
py cycles had significantly unfavourable OS and PFS (five-year 
OS: 50.1%, two-year PFS: 22.2%) compared to that in patients 
who demonstrated normal CA125 values (five-year OS: 73.4%, 
two-year PFS: 55.0%) (p<0.001) (Fig. 2).
Table 3. Multivariate Analysis of CA125-Related Prognostic Factors for Overall Survival and Progression Free Survival
Prognostic factor Categories
OS PFS
p value HR (95% CI) p value HR (95% CI)
After 1st CTx
≤35 u/mL 1 1 
>35 u/mL <0.001 3.68 (1.96–6.91) 0.001 1.82 (1.28–2.60)
Time to normalization
≤3rd cycle 1 1 
>3rd cycle 0.028 2.00 (1.08–3.71) <0.001 2.91 (1.85–4.59)
Relative change (base–after 1st CTx)
≤71% 1 -
>71% 0.021 0.52 (0.29–0.90)
Pre-operative CA125
≤500 u/mL - -
>500 u/mL
After 2nd CTx
≤35 u/mL - -
>35 u/mL
After 6th CTx
≤9 u/mL - -
>9 u/mL
Nadir
≤8 u/mL - -
>8 u/mL
CA125 half-life
≤3 days - -
>3 days
OS, overall survival; PFS, progression free survival; CI, confidence interval; HR, hazard ratio; CTx, chemotherapy; CA125, cancer antigen 125.
Fig. 1. Kaplan-Meier survival plot for overall survival and progression free survival according to CA125 after 1st cycle of chemotherapy. CA125, cancer 
antigen 125.
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DISCUSSION
The main finding of this study was that serum CA125 levels 
≤35 U/mL after the first cycle of chemotherapy and normaliza-
tion of CA125 levels within three cycles of chemotherapy were 
the most significant prognostic factors for both OS and PFS.
Until now, an alternative to CA125 has not been identified for 
screening and monitoring EOC or for use as a prognostic indi-
cator. Therefore, many studies continue to investigate the rela-
tionship between CA125 and ovarian cancer prognosis.
The predictive and prognostic values of baseline CA125 con-
centrations, which are measured before initiating treatment, 
have been previously described.24-26 However, CA125 has limit-
ed applications in all stages of EOC, as 7.6% of patients with ad-
vanced EOC show normal CA125 levels (< or =35 U/mL).24 An-
other major limitation of this simple approach is that baseline 
values measured before the initiation of treatment do not in-
tegrate the effect of treatment on subsequent CA125 titers.
CA125 normalization at the end of six chemotherapy cycles 
was reported as a predictive factor in Gynecology Oncology 
Group trials5 and during the third cycle in two other studies.4,27 
These results are consistent with our main results. Similar 
conclusions have also been made regarding the value of CA125 
normalization after neoadjuvant chemotherapy in patients 
with advanced ovarian cancer.28,29 The nadir has been used to 
analyse the kinetics of CA125 in ovarian cancer patients,6,12,30,31 
but the reported thresholds are inconsistent. Furthermore, it 
should be noted that the predicted level of decrease in CA125 
percentages has been reported in metastatic ovarian cancer 
patients.23,32-34 In 2004, the GCIC defined a CA125 response to 
treatment as a 50% reduction in CA125 levels maintained for 
at least 28 days.7 However, in the CALYPSO trial, an early de-
cline in CA125 was more frequent in the detrimental arm,8 and 
the reproducibility of the surrogate values for the percentage 
decrease remains debatable.
The aim of this study was to determine the most significant 
and reliable prognostic factors for OS and PFS among the 
known CA125-related prognostic factors and to provide cut-off 
values that reflect differences in prognosis when subdivided 
into two groups. To investigate if this trend was similar to pre-
viously reported trends, univariate analysis of 10 factors was 
performed in the patients included in this study. Statistically 
significant outcomes were obtained for eight factors except for 
time to nadir and relative percentage change between base-
line and after the second chemotherapy cycle.
Because the cut-off CA125 level after the first chemotherapy 
cycle was 35 U/mL and the time to normalization was the third 
cycle, two checkpoints should be considered when evaluating 
the prognosis of patients with advanced ovarian cancer after 
debulking surgery and POAC. First, the CA125 level after the 
first chemotherapy cycle (≤35 or >35 U/mL) can primarily 
classify good prognosis versus poor prognosis. CA125 levels in 
the normal range after the third chemotherapy cycle may allow 
clinicians to predict patient prognosis. In contrast to CA125 
kinetics, such as relative percentage change, half-life, and time 
to nadir, the CA125-related prognostic factors confirmed in this 
study are convenient and can determine whether the CA125 
levels after the first and third chemotherapy cycles are less than 
the normal reference value of 35 U/mL. Therefore, when pa-
tients have a poor prognosis according to the two checkpoints, 
chemotherapy dose, interval, cycle number, and regimen sho-
uld be reviewed.
This study had several limitations. First, the retrospective 
nature of the study and potential selection bias might have af-
fected our results. Second, due to a high percentage of patients 
without a confirmed pre-chemotherapy CA125 level, pre-che-
motherapy CA125 was not included as a variable in this study. 
However, through multivariate analysis in a multicentre retro-
Fig. 2. Kaplan-Meier survival plot for overall survival and progression free survival according to the timing of normalization of CA125. CA125, cancer 
antigen 125.
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spective study with 494 subjects, Riedinger, et al.23 determined 
that patients with normal baseline CA125 levels or patients 
who showed a >50% decrease to <35 U/mL before the second 
chemotherapy cycle had a favourable prognosis. The above 
authors observed, statistically significant differences in prog-
nosis, confirming that this was the most significant prognostic 
factor; consistent with our present results.
In conclusion, absolute CA125 levels measured after the first 
chemotherapy cycle (cut-off value: 35 U/mL) and normaliza-
tion of CA125 levels up to the third chemotherapy cycle were 
the most significant prognostic factors for predicting OS and 
PFS in patients with advanced serous ovarian cancer. There-
fore, during first-line chemotherapy, subsets of patients can 
be predicted to have poor prognosis by routinely measuring 
CA125 levels. Based on these analyses, treatment plans can be 
changed to improve patient prognosis. Finally, a reasonable 
study might randomize patients with EOC whose serum CA125 
levels fail to normalize after the initial three chemotherapy cy-
cles to either continued platinum or taxane chemotherapy or 
to a ‘novel’ antineoplastic regimen whose composition re-
mains to be determined.
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